KIORA PHARMACEUTICALS INCKPRXEarnings & Financial Report
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for ophthalmic diseases, including retinal disorders, uveitis, and other conditions with high unmet medical needs. It operates in the global biopharmaceutical market, targeting patient populations with limited existing treatment options.
KPRX Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
KIORA PHARMACEUTICALS INC Q4 FY2025 Financial Summary
KIORA PHARMACEUTICALS INC reported revenue of $0 for Q4 FY2025, with a net profit of N/A (down 54.3% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
KIORA PHARMACEUTICALS INC Annual Revenue by Year
KIORA PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
KIORA PHARMACEUTICALS INC Quarterly Revenue & Net Profit History
KIORA PHARMACEUTICALS INC results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | N/A | N/A |
| Q3 FY2025 | $0 | — | $26.8K | N/A |
| Q2 FY2025 | $0 | — | $-2.2M | N/A |
| Q1 FY2025 | $0 | — | $-2.2M | N/A |
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $0 | — | $-3.4M | N/A |
| Q1 FY2024 | $16.0M | — | $13.5M | 84.1% |
Income Statement
| Q1 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $16.0M | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Assets | $42.4M | $38.5M | $36.5M | $34.0M | $31.9M | $29.9M | $24.3M |
| Liabilities | $7.5M | $8.5M | $10.7M | $10.3M | $9.8M | $7.5M | $8.1M |
| Equity | $34.9M | $30.0M | $25.8M | $23.7M | $22.1M | $22.4M | $16.1M |
Cash Flow
| Q1 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $13.6M | $920057 | $8.6M | $-2.7M | $-3.8M | $-1.3M | $-10.0M |